Results pending
Cholecalciferol: reduce relapses and new lesions in relapsing MS
relapsing MS · Vitamin D and nutritional supplements
Trials have finished, but some results have not been read yet. There is no verdict until they are, because one unread trial can change the answer.
- Trials
- 8
- Running now
- 0
- Controlled phase 2/3 trials
- 2
- People in controlled trials
- 209
How the verdict was reached
Phase 2 results not all read yet
| Trial | Phase | Participants | Started | Result | Counted |
|---|---|---|---|---|---|
| EVIDIMS | Phase 2 | 80 | 2011 | Missed its main goal After 18 months, clinical (relapse rates, disability progression) and radiographical (T2-weighted lesion development, contrast-enhancing lesion development, brain atrophy) did not differ between both treatment arms. Paper abstract | Counted |
| CHOLINE | Phase 2 | 129 | 2009 | Missed its main goal | Counted |
| VITADEM | Phase 2 | 100 | 2012 | No results found | Not counted: added on top of a medicine that already controls relapses, so a miss says little |
| Cholecalciferol, phase 1 | Phase 1 | Not reported | 1998 | No results found | Not counted: not randomised |
| SOLAR | Phase 2 | 260 | 2011 | Missed its main goal At 48 weeks, 36.3% of patients who received high-dose vitamin D 3 had NEDA-3, without a statistically significant difference in NEDA-3 status between groups (placebo 35.3%; odds ratio 0.93; 95% confidence interval [CI] 0.53-1.63; p = 0.80). Paper abstract | Not counted: added on top of a medicine that already controls relapses, so a miss says little |
| Cholecalciferol, phase 3 | Phase2|phase3 | 70 | 2008 | Missed its main goal Median change in BOD was 287 mm(3) in the placebo group and 83 mm(3) in the vitamin D group (p=0.105). Paper abstract | Not counted: added on top of a medicine that already controls relapses, so a miss says little |
| Cholecalciferol, phase 3 | Phase 3 | 172 | 2012 | Missed its main goal | Not counted: not randomised |
| Cholecalciferol, phase 4 | Phase 4 | 54 | 2022 | No results found | Not counted: not randomised |
Counted: 2. Will count later: 0. Not counted: 6.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- Oct 2026First listed as Results pending
Related hypotheses
- Vitamin D and nutritional supplements: protect nerve tissue in relapsing MS
- Fish oil: protect nerve tissue in relapsing MS
- Melatonin: protect nerve tissue in relapsing MS
- Fish oil: repair myelin in relapsing MS
- Vitamin D and nutritional supplements: slow disability worsening in relapsing MS
- Ergocalciferol: slow disability worsening in relapsing MS
- Fish oil: slow disability worsening in relapsing MS
- Melatonin: slow disability worsening in relapsing MS
- Retinol: slow disability worsening in relapsing MS
- Vitamin D and nutritional supplements: reduce relapses and new lesions in relapsing MS
- Cholecalciferol: reduce relapses and new lesions in MS (type not specified)
- Curcumin: reduce relapses and new lesions in relapsing MS
- Fish oil: reduce relapses and new lesions in relapsing MS
- Melatonin: reduce relapses and new lesions in relapsing MS
- Omega-3 fatty acids: reduce relapses and new lesions in relapsing MS
- Retinol: reduce relapses and new lesions in relapsing MS